Rua Bioscience (RUA) AGM 2025 summary

Opening remarks and agenda

• Chair welcomed attendees, outlined the pivotal year, and explained online participation, including Q&A and voting procedures.

• Agenda included operational and financial updates, company overview, Chair's address, CEO presentation, shareholder questions, resolutions, and general business.

• Quorum confirmed with over 41 million valid proxies lodged.

Financial performance review

• Customer revenue rose to NZD 1.5 million from NZD 86,000 in FY24; total revenue reached NZD 1.9 million in FY25.

• Loss before tax reduced to NZD 3.5 million from NZD 13.7 million in FY24.

• Cash and investments at year-end were NZD 241,000, with net assets of NZD 4.89 million.

• Operating cash outflows decreased to NZD 2.79 million, with NZD 2.02 million inflow from financing activities.

• Overheads reduced from NZD 600,000/month in 2022 to NZD 284,000/month in 2025.

Board and executive committee updates

• Board chaired by Anna Stove, with directors Panapa Ehau, Teresa Ciprian, Tony Barclay, and observer Kale Panoho; diversity and inclusion emphasized.

• New Board Observer appointed as part of a Māori director development program.

• Board meetings scheduled according to the Maramataka lunar calendar.